STORM Therapeutics
Clinical-stage biotech company targeting RNA modifications for novel cancer therapies.
About
STORM Therapeutics is a clinical-stage biotechnology company focused on developing novel cancer therapies by targeting RNA modifications. Their lead candidate, STC-15, is the first RNA-modifying enzyme inhibitor to enter human clinical trials, specifically inhibiting METTL3, an enzyme crucial for regulating cancer stem cell differentiation. The company aims to reprogram malignant cells and treat diseases, with a current focus on sarcomas and other malignancies. Teams look it up for Biotechnology, Pharmaceuticals, Oncology.
Frequently asked
What does STORM Therapeutics do?
STORM Therapeutics is a Biotechnology company that offers Services. Teams look it up for Pharmaceuticals, Oncology, RNA Therapeutics. It is based in Cambridge, England, United Kingdom and was founded in 2015. Public records show $58M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has STORM Therapeutics raised?
STORM Therapeutics has raised a total of $58M in funding. The most recent round on record is Seed.
Where is STORM Therapeutics headquartered?
STORM Therapeutics is headquartered in Cambridge, England, United Kingdom.
When was STORM Therapeutics founded?
STORM Therapeutics was founded in 2015.
What industry does STORM Therapeutics operate in?
STORM Therapeutics operates in Biotechnology, Pharmaceuticals, Oncology, RNA Therapeutics.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.